McVean: The MiniMed 780G delivers insulin dynamically every five minutes to maximize the time in range and minimize the highs and the lows. Every five minutes, it automatically delivers the basal or background insulin to target a glucose, and the choices are 100 mg/dL, 110 mg/dL and 120 mg/dL, and the recommended target to achieve the maximum time in range is 100 mg/dL. There is no other system that is able to target 100 mg/dL – that’s the closest to what the pancreas would actually do. In addition, it has the ability to auto-correct.

If the glucose is elevated as often as every five minutes, it can give an auto correction to bring the patient back down. That's important, because every time, before someone with diabetes eats, they have to bolus, they have to enter their carbs. People can be inaccurate. If someone has forgotten to enter in their carbs or not entered in enough, then the system will see that rise in glucose and it will kick in those auto corrections to bring them back down. So really, the 780G is quite revolutionary in combating hyperglycemia. In the US, unfortunately, the minority of people living with type 1 diabetes are achieving the less than 7% hemoglobin A1C and the over 70% time in range. The reason for that is too many highs, and if there are too many high blood sugars, there are acute complications like diabetic ketoacidosis. It also impacts the developing brain in children and adolescents and there are also long- term complications, eye disease, kidney disease, heart disease. The metabolic goals are met more frequently in Europe.

‘Closest To What The Pancreas Would Actually Do’: Medtronic Diabetes Execs On Marketing Plans For MiniMed 780G

Discuss Plans For MiniMed 780G, One-StopShopping For Diabetes Tech

More from Strategy

More from Business